Next Article in Journal
BMP-7 Treatment Ameliorates PTEN-Akt Mediated Apoptosis and Adverse Cardiac Remodeling in Ponatinib-Induced Cardiotoxicity
Previous Article in Journal
Study on the Efficacy and Pharmacological Mechanism of Innate Immune STING Pathway Regulators in the Treatment of Ischemic Brain Injury
Previous Article in Special Issue
Computational Chemistry Advances in the Development of PARP1 Inhibitors for Breast Cancer Therapy
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Review

Docking in the Dark: Insights into Protein–Protein and Protein–Ligand Blind Docking

by
Muhammad Sohaib Roomi
1,
Giulia Culletta
1,*,
Lisa Longo
1,2,
Walter Filgueira de Azevedo, Jr.
3,
Ugo Perricone
4 and
Marco Tutone
1
1
Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123 Palermo, Italy
2
Biophysics Institute, National Research Council, 90146 Palermo, Italy
3
Department of Physics, Institute of Exact Sciences, Federal University of Alfenas, Alfenas 37130-001, Brazil
4
Molecular Informatics Group, Ri.MED Foundation, 90133 Palermo, Italy
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2025, 18(12), 1777; https://doi.org/10.3390/ph18121777 (registering DOI)
Submission received: 29 September 2025 / Revised: 17 November 2025 / Accepted: 19 November 2025 / Published: 22 November 2025

Abstract

Blind docking predicts binding interactions between two molecular entities without prior knowledge of the binding site. This approach is essential because it explores the entire surface of the receptor to identify potential interaction sites. Blind docking widely works for both protein–protein and ligand–protein interaction studies. In protein–protein blind docking, the method aims to predict the correct orientation and interface of two proteins forming a complex. Protein blind docking is particularly valuable in studying transient interactions, protein–protein recognition, signaling pathways, tentative and significant biomolecular assemblies where structural data is limited. Ligand–protein blind docking discovers potential binding pockets across the entire protein surface. It is frequently applied in early-stage drug discovery, especially for novel or poorly characterized targets. The method helps identify allosteric sites or novel binding regions that are not evident from known structures. Overall, blind docking provides a versatile and powerful tool for studying molecular interactions, enabling discovery even in the absence of detailed structural information. In this scenario, we reported a timeline of attempts to improve this kind of computational approach with ML and hybrid approaches to obtain more reliable predictions. We dedicate two main sections to protein–protein and protein-ligand blind docking, presenting the reliability and caveats for each approach and outlining potential future directions.
Keywords: blind docking; protein–protein docking; small molecule-protein docking; ligand-protein docking; blind docking tools blind docking; protein–protein docking; small molecule-protein docking; ligand-protein docking; blind docking tools
Graphical Abstract

Share and Cite

MDPI and ACS Style

Roomi, M.S.; Culletta, G.; Longo, L.; Azevedo, W.F.d., Jr.; Perricone, U.; Tutone, M. Docking in the Dark: Insights into Protein–Protein and Protein–Ligand Blind Docking. Pharmaceuticals 2025, 18, 1777. https://doi.org/10.3390/ph18121777

AMA Style

Roomi MS, Culletta G, Longo L, Azevedo WFd Jr., Perricone U, Tutone M. Docking in the Dark: Insights into Protein–Protein and Protein–Ligand Blind Docking. Pharmaceuticals. 2025; 18(12):1777. https://doi.org/10.3390/ph18121777

Chicago/Turabian Style

Roomi, Muhammad Sohaib, Giulia Culletta, Lisa Longo, Walter Filgueira de Azevedo, Jr., Ugo Perricone, and Marco Tutone. 2025. "Docking in the Dark: Insights into Protein–Protein and Protein–Ligand Blind Docking" Pharmaceuticals 18, no. 12: 1777. https://doi.org/10.3390/ph18121777

APA Style

Roomi, M. S., Culletta, G., Longo, L., Azevedo, W. F. d., Jr., Perricone, U., & Tutone, M. (2025). Docking in the Dark: Insights into Protein–Protein and Protein–Ligand Blind Docking. Pharmaceuticals, 18(12), 1777. https://doi.org/10.3390/ph18121777

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Article metric data becomes available approximately 24 hours after publication online.
Back to TopTop